Sanofi (NASDAQ:SNY) Shares Sold by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI lessened its stake in shares of Sanofi (NASDAQ:SNY) by 45.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,065 shares of the company’s stock after selling 11,650 shares during the quarter. Parsons Capital Management Inc. RI’s holdings in Sanofi were worth $684,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Boston Partners increased its position in Sanofi by 1.9% during the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock worth $648,617,000 after buying an additional 245,682 shares during the period. Morgan Stanley grew its position in shares of Sanofi by 4.6% during the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after acquiring an additional 323,968 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Sanofi by 29.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after acquiring an additional 651,756 shares during the period. Natixis Advisors L.P. raised its position in Sanofi by 15.9% in the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after purchasing an additional 346,563 shares during the last quarter. Finally, Raymond James & Associates boosted its stake in Sanofi by 26.9% during the 1st quarter. Raymond James & Associates now owns 2,315,255 shares of the company’s stock worth $112,521,000 after purchasing an additional 491,498 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded down $0.23 during midday trading on Friday, hitting $49.13. The stock had a trading volume of 4,148,180 shares, compared to its average volume of 2,214,580. Sanofi has a 1 year low of $42.63 and a 1 year high of $56.26. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average price of $47.71 and a two-hundred day moving average price of $48.32. The company has a market capitalization of $124.28 billion, a PE ratio of 24.69, a P/E/G ratio of 1.48 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. As a group, equities analysts predict that Sanofi will post 4.09 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 69.35%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SNY. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.